- Home
- FSEA vs LUNG Comparison
FSEA vs LUNG Comparison
Compare FSEA & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSEA
- LUNG
- Stock Information
- Founded
- FSEA 1890
- LUNG 1995
- Country
- FSEA United States
- LUNG United States
- Employees
- FSEA N/A
- LUNG N/A
- Industry
- FSEA Savings Institutions
- LUNG Industrial Specialties
- Sector
- FSEA Finance
- LUNG Health Care
- Exchange
- FSEA Nasdaq
- LUNG Nasdaq
- Market Cap
- FSEA 54.1M
- LUNG 63.6M
- IPO Year
- FSEA N/A
- LUNG 2020
- Fundamental
- Price
- FSEA $11.95
- LUNG $1.52
- Analyst Decision
- FSEA
- LUNG Buy
- Analyst Count
- FSEA 0
- LUNG 7
- Target Price
- FSEA N/A
- LUNG $6.81
- AVG Volume (30 Days)
- FSEA 3.4K
- LUNG 6.9M
- Earning Date
- FSEA 11-14-2025
- LUNG 11-12-2025
- Dividend Yield
- FSEA N/A
- LUNG N/A
- EPS Growth
- FSEA N/A
- LUNG N/A
- EPS
- FSEA N/A
- LUNG N/A
- Revenue
- FSEA $14,753,000.00
- LUNG $91,664,000.00
- Revenue This Year
- FSEA N/A
- LUNG $10.41
- Revenue Next Year
- FSEA N/A
- LUNG $10.98
- P/E Ratio
- FSEA N/A
- LUNG N/A
- Revenue Growth
- FSEA 29.53
- LUNG 15.59
- 52 Week Low
- FSEA $9.00
- LUNG $1.47
- 52 Week High
- FSEA $11.95
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- FSEA 66.25
- LUNG 41.72
- Support Level
- FSEA $11.50
- LUNG $1.65
- Resistance Level
- FSEA $11.70
- LUNG $2.11
- Average True Range (ATR)
- FSEA 0.09
- LUNG 0.25
- MACD
- FSEA 0.02
- LUNG -0.02
- Stochastic Oscillator
- FSEA 100.00
- LUNG 2.47
About FSEA First Seacoast Bancorp Inc.
First Seacoast Bancorp Inc is a savings and loan holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one-to-four-family residential real estate loans, commercial real estate, and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. The company generates revenue from financial instruments, such as loans, letters of credit, and investment securities, as well as revenue related to mortgage servicing activities, and bank-owned life insurance.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.